Loading clinical trials...
Loading clinical trials...
A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity
Conditions
Interventions
calcium gluconate
magnesium sulfate
+2 more
Locations
405
United States
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
Fairbanks, Alaska, United States
Kaiser Permanente - Deer Valley
Antioch, California, United States
North Bay Cancer Center
Fairfield, California, United States
Kaiser Permanente - Fremont
Fremont, California, United States
Kaiser Permanente Fresno Medical Center
Fresno, California, United States
Kaiser Permanente Medical Center - Hayward
Hayward, California, United States
Start Date
June 1, 2010
Primary Completion Date
December 1, 2012
Completion Date
March 1, 2013
Last Updated
November 3, 2022
NCT02600949
NCT07446322
NCT05919264
NCT06614322
NCT07543991
NCT06290141
Lead Sponsor
Alliance for Clinical Trials in Oncology
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions